Understanding and Anticipating Therapeutic and ADverse Responses in Anti-cancer Immune Checkpoint Inhibition Towards a Better Therapeutic Management of Patients

Imagine your body's immune system as an army designed to fight off invaders like infections. Immunotherapy for cancer, specifically immune checkpoint inhibitors (ICIs), helps this army recognize and attack cancer cells more effectively. It works by removing the 'brakes' that stop immune cells from attacking cancer.

While this treatment can be very successful for some people, boosting the immune system in this way can sometimes lead to it overreacting and mistakenly attacking healthy parts of the body. These unwanted side effects are called immune-related adverse events, or irAEs. They can affect different organs, causing issues like skin rashes, gut problems, or thyroid problems. We don't yet fully understand why these side effects happen to some people and not others, or why some get good results from the treatment while others don't.

This study hopes to change that. We want to investigate whether we can find specific signals in your blood – called biomarkers – that can tell us early on who might be more likely to develop these side effects or who might respond well to immunotherapy. By collecting blood samples and health information from patients receiving these treatments as part of their routine care, we can look closely at how their immune systems are behaving. The goal is to gain a deeper understanding that will eventually help doctors predict and manage these treatments better, leading to improved care for future cancer patients.